1-20 of 73
liver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes

Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A. DeFronzo, Muhammad Abdul-Ghani
Journal: Diabetes Care
Diabetes Care 2024;47(4):668–675
https://doi.org/10.2337/dc23-1646
Published: 31 January 2024
View article titled, Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Open the PDF for Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes in another window
Journal Articles

Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes

Oana-Patricia Zaharia, Sofia Antoniou, Pavel Bobrov, Yanislava Karusheva, Kálmán Bódis, Yuliya Kupriyanova, Vera Schrauwen-Hinderling, Amalia Gastaldelli, Julia Szendroedi, Robert Wagner, Volker Burkart, Michael Roden, GDS Group, Michael Roden, Hadi Al-Hasani, Bengt Belgardt, Gidon Josia Bönhof, Gerd Geerling, Christian Herder, Andrea Icks, Karin Jandeleit-Dahm, Jörg Kotzka, Oliver Kuß, Eckhard Lammert, Wolfgang Rathmann, Sabrina Schlesinger, Vera Schrauwen-Hinderling, Julia Szendroedi, Sandra Trenkamp, Robert Wagner
Journal: Diabetes Care
Diabetes Care 2023;46(12):2232–2239
https://doi.org/10.2337/dc23-1267
Published: 24 October 2023
View article titled, Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes
Open the PDF for Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes in another window
Journal Articles

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
Journal: Diabetes Care
Diabetes Care 2022;45(9):2064–2075
https://doi.org/10.2337/dc21-2049
Published: 27 July 2022
View article titled, Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
Open the PDF for Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial in another window
Journal Articles

SGLT2i Increase Endogenous Glucose Production: That’s Good News!

Andrea Giaccari
Journal: Diabetes Care
Diabetes Care 2022;45(6):1301–1302
https://doi.org/10.2337/dci22-0010
Published: 27 May 2022
View article titled, SGLT2i Increase Endogenous Glucose Production: That’s Good News!
Open the PDF for SGLT2i Increase Endogenous Glucose Production: That’s Good News! in another window
Journal Articles

Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages?

Antoine Avignon
Journal: Diabetes Care
Diabetes Care 2022;45(5):1032–1034
https://doi.org/10.2337/dci22-0005
Published: 05 May 2022
View article titled, Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages?
Open the PDF for Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages? in another window
Journal Articles

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes

Sofiya Gancheva, Sabine Kahl, Dominik Pesta, Lucia Mastrototaro, Bedair Dewidar, Klaus Strassburger, Ehsan Sabah, Irene Esposito, Jürgen Weiß, Theresia Sarabhai, Martin Wolkersdorfer, Thomas Fleming, Peter Nawroth, Marcel Zimmermann, Andreas S. Reichert, Matthias Schlensak, Michael Roden
Journal: Diabetes Care
Diabetes Care 2022;45(4):928–937
https://doi.org/10.2337/dc21-1758
Published: 03 February 2022
View article titled, Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes
Open the PDF for Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes in another window
Journal Articles

Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study

Susan Martin, Elena P. Sorokin, E. Louise Thomas, Naveed Sattar, Madeleine Cule, Jimmy D. Bell, Hanieh Yaghootkar
Journal: Diabetes Care
Diabetes Care 2022;45(2):460–468
https://doi.org/10.2337/dc21-1262
Published: 17 January 2022
View article titled, Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study
Open the PDF for Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study in another window
Journal Articles

The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes

Erika B. Parente, Emma H. Dahlström, Valma Harjutsalo, Jussi Inkeri, Stefan Mutter, Carol Forsblom, Niina Sandholm, Daniel Gordin, Per-Henrik Groop
Journal: Diabetes Care
Diabetes Care 2021;44(7):1706–1713
https://doi.org/10.2337/dc20-3175
Published: 24 May 2021
View article titled, The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes
Open the PDF for The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes in another window
Journal Articles

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

Bruno Vergès, Laurence Duvillard, Jean Paul Pais de Barros, Benjamin Bouillet, Sabine Baillot-Rudoni, Alexia Rouland, Jean Michel Petit, Pascal Degrace, Laurent Demizieux
Journal: Diabetes Care
Diabetes Care 2021;44(4):1027–1037
https://doi.org/10.2337/dc20-1843
Published: 02 February 2021
View article titled, Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
Open the PDF for Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression in another window
Journal Articles

Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery

Roman Vangoitsenhoven, Rickesha L. Wilson, Deepa V. Cherla, Chao Tu, Sangeeta R. Kashyap, David E. Cummings, Philip R. Schauer, Ali Aminian
Journal: Diabetes Care
Diabetes Care 2021;44(2):321–325
https://doi.org/10.2337/dc20-0150
Published: 15 December 2020
View article titled, Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery
Open the PDF for Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery in another window
Journal Articles

Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease

Kasper W. ter Horst, Daniel F. Vatner, Dongyan Zhang, Gary W. Cline, Mariette T. Ackermans, Aart J. Nederveen, Joanne Verheij, Ahmet Demirkiran, Bart A. van Wagensveld, Geesje M. Dallinga-Thie, Max Nieuwdorp, Johannes A. Romijn, Gerald I. Shulman, Mireille J. Serlie
Journal: Diabetes Care
Diabetes Care 2021;44(2):489–498
https://doi.org/10.2337/dc20-1644
Published: 08 December 2020
View article titled, Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
Open the PDF for Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease in another window
Journal Articles

Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?

Jelena Soldo, Martin Heni, Alfred Königsrainer, Hans-Ulrich Häring, Andreas L. Birkenfeld, Andreas Peter
Journal: Diabetes Care
Diabetes Care 2020;43(10):e134–e136
https://doi.org/10.2337/dc20-1458
Published: 11 September 2020
View article titled, Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?
Open the PDF for Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients? in another window
Journal Articles

The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial

Angelo Sabag, Kimberley L. Way, Rachelle N. Sultana, Shelley E. Keating, James A. Gerofi, Vivienne H. Chuter, Nuala M. Byrne, Michael K. Baker, Jacob George, Ian D. Caterson, Stephen M. Twigg, Nathan A. Johnson
Journal: Diabetes Care
Diabetes Care 2020;43(10):2371–2378
https://doi.org/10.2337/dc19-2523
Published: 30 July 2020
View article titled, The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial
Open the PDF for The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial in another window
Journal Articles

Role of Patatin-Like Phospholipase Domain–Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes

Oana P. Zaharia, Klaus Strassburger, Birgit Knebel, Yuliya Kupriyanova, Yanislava Karusheva, Martin Wolkersdorfer, Kálmán Bódis, Daniel F. Markgraf, Volker Burkart, Jong-Hee Hwang, Jörg Kotzka, Hadi Al-Hasani, Julia Szendroedi, Michael Roden, GDS Group, M. Roden, H. Al-Hasani, V. Burkart, A.E. Buyken, J. Eckel, G. Geerling, J.H. Hwang, C. Herder, A. Icks, K. Jandeleit-Dahm, S. Kahl, J. Kotzka, O. Kuss, E. Lammert, S. Trenkamp, W. Rathmann, J. Szendroedi, D. Ziegler
Journal: Diabetes Care
Diabetes Care 2020;43(9):2161–2168
https://doi.org/10.2337/dc20-0329
Published: 19 June 2020
View article titled, Role of Patatin-Like Phospholipase Domain–Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes
Open the PDF for Role of Patatin-Like Phospholipase Domain–Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes in another window
Journal Articles

In This Issue of Diabetes Care

Journal: Diabetes Care
Diabetes Care 2020;43(2):263–264
https://doi.org/10.2337/dc20-ti02
Published: 13 January 2020
View article titled, In This Issue of <em>Diabetes Care</em>
Open the PDF for In This Issue of <em>Diabetes Care</em> in another window
Journal Articles

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

Zobair M. Younossi, Radhika P. Tampi, Andrei Racila, Ying Qiu, Leah Burns, Issah Younossi, Fatema Nader
Journal: Diabetes Care
Diabetes Care 2020;43(2):283–289
https://doi.org/10.2337/dc19-1113
Published: 28 October 2019
View article titled, Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Open the PDF for Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. in another window
Includes: Supplementary data
Journal Articles

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes

David Klonoff, Bruce Bode, Nathan Cohen, Marc Penn, W. Blair Geho, Douglas B. Muchmore
Journal: Diabetes Care
Diabetes Care 2019;42(11):2154–2157
https://doi.org/10.2337/dc19-0152
Published: 24 September 2019
View article titled, Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes
Open the PDF for Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch, Konstantinos Kantartzis, Yuliya Kupriyanova, Daniel Markgraf, Theresa van Gemert, Birgit Knebel, Martin F. Wolkersdorfer, Oliver Kuss, Jong-Hee Hwang, Stefan R. Bornstein, Christian Kasperk, Norbert Stefan, Andreas Pfeiffer, Andreas L. Birkenfeld, Michael Roden
Journal: Diabetes Care
Diabetes Care 2020;43(2):298–305
https://doi.org/10.2337/dc19-0641
Published: 20 September 2019
View article titled, Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open the PDF for Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Fernando Bril, Diane M. Biernacki, Srilaxmi Kalavalapalli, Romina Lomonaco, Sreevidya K. Subbarayan, Jinping Lai, Fermin Tio, Amitabh Suman, Beverly K. Orsak, Joan Hecht, Kenneth Cusi
Journal: Diabetes Care
Diabetes Care 2019;42(8):1481–1488
https://doi.org/10.2337/dc19-0167
Published: 21 May 2019
View article titled, Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Open the PDF for Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K. Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson, Jan Oscarsson, Jarna C. Hannukainen, Pirjo Nuutila
Journal: Diabetes Care
Diabetes Care 2019;42(5):931–937
https://doi.org/10.2337/dc18-1569
Published: 18 March 2019
View article titled, The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Open the PDF for The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients in another window
Includes: Supplementary data